Back

Raymond James analyst raises Dyne Therapeutics target to $37, implying 80.75% upside

Verifying
  • Michael Freeman raised Dyne Therapeutics’ price target to $37.
  • 80.75% upside was indicated from the current price around $20.60.
  • Dyne Therapeutics is advancing treatments for muscle diseases.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.